These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31952674)

  • 1. Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review.
    Gorry C; McCullagh L; Barry M
    Value Health; 2020 Jan; 23(1):52-60. PubMed ID: 31952674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.
    Pike E; Hamidi V; Saeterdal I; Odgaard-Jensen J; Klemp M
    BMJ Open; 2017 Aug; 7(8):e014880. PubMed ID: 28827234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review.
    Rubio-Rodríguez D; De Diego Blanco S; Pérez M; Rubio-Terrés C
    Pharmacoeconomics; 2017 Sep; 35(9):879-893. PubMed ID: 28551858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
    Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer.
    Sharma S; Carey N; McConnell D; Lowery M; O'Sullivan J; McCullagh L;
    Pharmacoeconomics; 2024 Oct; 42(10):1091-1110. PubMed ID: 39060831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
    Meng Y; Hertel N; Ellis J; Morais E; Johnson H; Philips Z; Roskell N; Walker A; Lee D
    Eur J Health Econ; 2018 Nov; 19(8):1163-1172. PubMed ID: 29524005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
    Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
    J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
    [No Abstract]   [Full Text] [Related]  

  • 8. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.
    Matter-Walstra K; Braun R; Kolb C; Ademi Z; Dummer R; Pestalozzi BC; Schwenkglenks M
    Br J Dermatol; 2015 Dec; 173(6):1462-70. PubMed ID: 26332527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.
    Bohensky MA; Pasupathi K; Gorelik A; Kim H; Harrison JP; Liew D
    Value Health; 2016 Dec; 19(8):1009-1015. PubMed ID: 27987627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accounting for Cured Patients in Cost-Effectiveness Analysis.
    Othus M; Bansal A; Koepl L; Wagner S; Ramsey S
    Value Health; 2017 Apr; 20(4):705-709. PubMed ID: 28408015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
    Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C
    Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
    Oh A; Tran DM; McDowell LC; Keyvani D; Barcelon JA; Merino O; Wilson L
    J Manag Care Spec Pharm; 2017 Jun; 23(6):653-664. PubMed ID: 28530525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced cutaneous malignant melanoma: a systematic review of economic and quality-of-life studies.
    Cashin RP; Lui P; Machado M; Hemels ME; Corey-Lisle PK; Einarson TR
    Value Health; 2008; 11(2):259-71. PubMed ID: 18380638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.
    Almutairi AR; Alkhatib NS; Oh M; Curiel-Lewandrowski C; Babiker HM; Cranmer LD; McBride A; Abraham I
    JAMA Dermatol; 2019 Jan; 155(1):22-28. PubMed ID: 30477000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal.
    Miguel LS; Lopes FV; Pinheiro B; Wang J; Xu R; Pellissier J; Laires PA
    Value Health; 2017 Sep; 20(8):1065-1073. PubMed ID: 28964438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.
    Fleeman N; Bagust A; Beale S; Boland A; Dickson R; Dwan K; Richardson M; Dundar Y; Davis H; Banks L
    Pharmacoeconomics; 2015 Sep; 33(9):893-904. PubMed ID: 25906420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada.
    Delea TE; Amdahl J; Wang A; Amonkar MM; Thabane M
    Pharmacoeconomics; 2015 Apr; 33(4):367-80. PubMed ID: 25488880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma.
    Tarhini A; McDermott D; Ambavane A; Gupte-Singh K; Aponte-Ribero V; Ritchings C; Benedict A; Rao S; Regan MM; Atkins M
    Immunotherapy; 2019 Mar; 11(4):283-295. PubMed ID: 30563395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma.
    Li M; Basu A; Bennette C; Veenstra D; Garrison LP
    Value Health; 2019 Jul; 22(7):777-784. PubMed ID: 31277824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.